Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Incyte Corporation
Phase 1/2
84
Cardiff, Boston, Lincoln, Truro
2021-03-19
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
London, Oxford, Sutton
2021-03-18
Active, closed
Gemma Biotherapeutics
Phase 1/2
26
London
2021-03-17
Active, closed
Novartis Pharmaceuticals
Phase 2
103
Sheffield, London
2021-03-15
Active, closed
Hoffmann-La Roche
Phase 1/2
241
London
2021-03-15
Active, closed
Janssen Research & Development, LLC
Phase 1
140
London, Manchester, Surrey
2021-03-12
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
London, Oxford, Boston, Liverpool, Newcastle upon Tyne
2021-03-11
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Aberdeen, Truro, Plymouth, Cottingham, London, Norwich, Swansea, Edinburgh
2021-03-09
Active, closed
BioNTech SE
Phase 2
327
Bebington, Birmingham, Cardiff, Cottingham, Dorchester, Glasgow, London, Manchester
2021-03-08
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Bristol, Cardiff, Glasgow, London
2021-03-04
Active, closed
LifeSprout, Inc.
Not applicable
118
London
2021-03-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Aberdeen, Bath, Nottingham, Southend, London, Northwood, Taunton, Swansea
2021-02-25
Active, closed
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Phase 3
455
London, Sutton
2021-02-25
Active, closed
Celgene
Phase 3
313
Nottingham, Birmingham, Boston, Oxford
2021-02-25
Active, closed
Hoffmann-La Roche
Phase 3
270
Glasgow, Leeds, London, Manchester, Nottingham
2021-02-23
Active, closed
Incyte Corporation
Phase 1
140
Boston, Lincoln, Manchester, Oxford
2021-02-23
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Birmingham, Edinburgh, Glasgow, Leicester, Manchester
2021-02-23
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
London, Birmingham, Hampshire
2021-02-23
Recruiting
Kartos Therapeutics, Inc.
Phase 1/2
84
Leeds, London, Southampton
2021-02-23
Recruiting
Biosense Webster, Inc.
Observational
8,000
Leicester, London
2021-02-22
Active, closed
M.A. Med Alliance S.A.
Not applicable
723
Frimley, Leicester, London, Redhill
2021-02-08
Active, closed
Hoffmann-La Roche
Phase 3
55
Glasgow
2021-02-04
Recruiting
Apellis Pharmaceuticals, Inc.
Phase 2
12
London
2021-02-04
Active, closed
Daiichi Sankyo
Phase 2
277
Birmingham, London, Manchester
2021-02-02
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
Active, closed
AstraZeneca
Phase 3
1,370
Cambridge, Colchester, Leeds, Nottingham, Surrey
2021-01-28
Recruiting
Artios Pharma Ltd
Phase 1/2
542
Glasgow, London, Manchester
2021-01-27
Recruiting
BioInvent International AB
Phase 1/2
250
Birmingham, Leicester, London, Manchester, Southampton
2021-01-25
Active, closed
NeoTract, Inc.
Not applicable
120
Frimley, Norwich, Cambridge
2021-01-22
By invitation
Vertex Pharmaceuticals Incorporated
Phase 3
160
London
2021-01-20
Active, closed
Hoffmann-La Roche
Phase 2
920
Glasgow, London, Manchester
2021-01-18
Active, closed
Pfizer
Phase 3
257
London, Swansea
2021-01-15
Recruiting
Pfizer
Phase 3
2,100
Leicester, London
2021-01-15
Active, closed
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
5,000
Bath, Belfast, Cardiff, Chippenham, Craigavon, Darlington, Durham, Hampshire
2021-01-15
Active, closed
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
Galderma R&D
Phase 3
500
Dudley, Glasgow, London, Newcastle upon Tyne
2021-01-11
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
217
London, Sutton
2021-01-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
BioNTech SE
Phase 2/3
358
Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2021-01-07
Recruiting
Change Accelerator in Respiratory Care
Observational
4,550
London
2021-01-01
Active, closed
Replimune, Inc.
Phase 1
123
Bebington, London, Oxford
2020-12-29
Active, closed
AstraZeneca
Phase 1/2
245
Buckhurst Hill
2020-12-28
Active, closed
Stryker Neurovascular
Observational
405
Birmingham, Edinburgh
2020-12-21
Active, closed
Daiichi Sankyo
Phase 3
605
London, Manchester, Middlesbrough
2020-12-21
Active, closed
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
Verastem, Inc.
Phase 2
225
Edinburgh, Glasgow, London, Manchester, Sutton
2020-12-21
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
Janssen Research & Development, LLC
Phase 2
220
Glasgow, Leeds
2020-12-18
Active, closed
Novartis Pharmaceuticals
Phase 2
17
London
2020-12-18
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
370
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
400
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-16
Active, closed
Neurocrine Biosciences
Phase 3
182
Cardiff, London, Manchester, Salford
2020-12-16
Active, closed
Boston Scientific Corporation
Observational
250
Liverpool, Oxford
2020-12-16
Active, closed
AstraZeneca
Phase 3
358
Birmingham, Liverpool
2020-12-16
Active, closed
Principia Biopharma, a Sanofi Company
Phase 3
232
London, Harrow, Manchester, Norfolk, Southampton
2020-12-14
Active, closed
Novartis Pharmaceuticals
Phase 3
404
Bristol, Hertford, Leicester, London, Salford
2020-12-11
Active, closed
GlaxoSmithKline
Phase 2/3
758
Cardiff, Edinburgh, London, Manchester
2020-12-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Aberdeen, Dundee, Taunton, London, Manchester
2020-12-08
Active, closed
Daiichi Sankyo
Phase 3
1,600
Peterborough, Maidstone, Manchester, Metropolitan Borough of Wirral, Nottingham, Bath, Taunton, Leeds
2020-12-04
Active, closed
Amgen
Phase 3
135
Leeds, London, Newcastle, Oxford
2020-12-04
Active, closed
Janssen Research & Development, LLC
Phase 3
97
Edinburgh, Glasgow, Leeds, London
2020-12-04
Active, closed
Hoffmann-La Roche
Phase 3
769
London, Newcastle upon Tyne, Plymouth
2020-12-03
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
2020-12-02
Active, closed
Abbott Medical Devices
Not applicable
200
Edinburgh, Brighton, Cambridge
2020-12-01
Active, closed
Hoffmann-La Roche
Phase 2
303
Harlow, London, Nottingham, Peterborough
2020-11-27
Active, closed
Hoffmann-La Roche
Phase 3
864
Plymouth
2020-11-26
Active, closed
XVIVO Perfusion
Not applicable
230
Newcastle, Birmingham, Cambridge
2020-11-25
Active, closed
Science Corporation
Not applicable
38
London
2020-11-24
Active, closed
Medicago
Phase 2/3
30,918
Aberdeen, Birmingham, Bournemouth, Cardiff, Chelmsford, Chorley, Derby, Harrow
2020-11-19
Active, closed
AstraZeneca
Phase 3
957
Cambridge, Dundee, Glasgow, Leicester, London, Manchester, Oxford, Surrey
2020-11-17
Active, closed
Eclipse Medical Ltd.
Not applicable
200
Brighton
2020-11-17
Active, closed
UCB Biopharma SRL
Phase 1
19
London, Southampton
2020-11-16
Active, closed
Janssen Research & Development, LLC
Phase 1
136
Newcastle upon Tyne
2020-11-13
Active, closed
AstraZeneca
Phase 1/2
702
Cambridge, Manchester, Oxford, Sutton
2020-11-12
Recruiting
Edwards Lifesciences
Not applicable
900
London
2020-11-12
Active, closed
Janssen Research & Development, LLC
Phase 1
158
Manchester, Sutton
2020-11-10
Active, closed
Bayer
Phase 4
654
Reading, Glasgow
2020-11-09
Active, closed
Prevail Therapeutics
Phase 1/2
35
London
2020-11-09
Active, closed
Pfizer
Phase 3
114
Newcastle upon Tyne, Liverpool, London
2020-11-05
Active, closed
Genmab
Phase 1/2
543
Manchester, Newcastle upon Tyne, Plymouth
2020-11-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Glasgow, London
2020-11-03
Recruiting
Ellipses Pharma
Phase 1/2
70
London, Manchester
2020-11-02
Recruiting
Cook Biotech Incorporated
Not applicable
40
Manchester
2020-11-01
Active, closed
Novartis Pharmaceuticals
Phase 2
134
Manchester
2020-10-30
Recruiting
PMV Pharmaceuticals, Inc
Phase 1/2
300
London, Newcastle upon Tyne
2020-10-29
Active, closed
Astellas Gene Therapies
Phase 1/2
11
Newcastle upon Tyne
2020-10-27
Active, closed
Hoffmann-La Roche
Phase 3
985
Glasgow, London, Nottingham, Swansea
2020-10-26
Active, closed
Provention Bio, a Sanofi Company
Observational
188
Sheffield
2020-10-26
Active, closed
Bayer
Phase 3
402
Reading, Colchester, London, Bebington, Scunthorpe, Glasgow, Cardiff, Llanelli
2020-10-20
Active, closed
Exelixis
Phase 3
575
London, Surrey Quays, Taunton, Blackburn, Northwood, Swansea
2020-10-19
Active, closed
Boston Scientific Corporation
Not applicable
3,000
Brighton, Leicester, Oxford
2020-10-15
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Edinburgh, London, Sutton
2020-10-13
Active, closed
BioMarin Pharmaceutical
Phase 2
20
London, Sheffield
2020-10-10
Active, closed
Hoffmann-La Roche
Phase 3
992
Brighton, Leicester, London, Maidstone, Peterborough, Plymouth, Sutton, Truro
2020-10-09
Active, closed
Hoffmann-La Roche
Phase 3
210
Leeds, London
2020-10-08
Recruiting
Medialis Ltd.
Observational
100
Oxford
2020-10-07
Active, closed
AstraZeneca
Phase 3
370
London, Manchester, Newcastle upon Tyne, Sutton
2020-10-02
Active, closed
GlaxoSmithKline
Phase 3
302
London, Plymouth, Southampton, Stoke-on-Trent, Sutton
2020-10-01
Active, closed
Spark Therapeutics, Inc.
Phase 1/2
4
Birmingham, London, Salford
2020-10-01
Recruiting
Smith & Nephew, Inc.
Observational
400
Manchester, Harpenden, Brighton, Burnley, Grantham, London, Bath, Hertford
2020-10-01